LY503430

LY503430 is a drug that was developed by Eli Lilly for potential use in the treatment of Alzheimer's disease and schizophrenia. It acts as an AMPA receptor positive allosteric modulator, which means it increases the activity of the AMPA receptor.

Pharmacology[edit | edit source]

LY503430 is a potent and selective AMPA receptor positive allosteric modulator. The AMPA receptor is one of the three main types of ionotropic glutamate receptors, the others being NMDA and kainate receptors. AMPA receptors mediate fast synaptic transmission in the central nervous system (CNS).

LY503430 enhances AMPA receptor function by increasing the amplitude of AMPA receptor-mediated currents and by slowing the rate of AMPA receptor desensitization. This results in an increase in synaptic plasticity, which is thought to be beneficial in the treatment of conditions such as Alzheimer's disease and schizophrenia.

Clinical Trials[edit | edit source]

LY503430 has undergone Phase I clinical trials for the treatment of Alzheimer's disease and schizophrenia. However, the results of these trials have not been publicly disclosed, and it is unclear whether the drug will proceed to Phase II trials.